Pfizer And Moderna’s Cold War On COVID Gets Competitive

Biotech Talks Up Refrigeration Advantage

Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.

Dry Ice
Dry ice pellets, like those that will be used to keep Pfizer/BioNTech's vaccine at -70°C

Pfizer/BioNTech and Moderna have now both presented Phase III efficacy data on their COVID-19 vaccines which far exceed earlier expectations, and look set to gain emergency use approvals (EUAs) by the end of the year.

In the remarkable sprint to develop a vaccine, all the company chiefs involved have agreed that the race is against...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip